Navigation Links
Sunesis Pharmaceuticals' SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
Date:12/10/2007

Phase 2 clinical trial in patients with ovarian cancer. SNS-032, Sunesis' potent and selective inhibitor of CDKs 2, 7 and 9, is being evaluated in a Phase 1 clinical trial in chronic lymphocytic leukemia and multiple myeloma. SNS-314, a potent and selective pan-Aurora kinase inhibitor, is being studied in a Phase 1 dose-escalating clinical trial in patients with advanced solid tumors. In addition, Sunesis is developing novel small molecule inhibitors of Raf kinase and receptor tyrosine kinases in collaboration with Biogen Idec.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com.

SUNESIS and the logo are trademarks of Sunesis Pharmaceuticals, Inc.

Safe Harbor Statement

This press release contains forward-looking statements including without limitation statements related to the potential safety and efficacy of SNS-595 and SNS-032 and planned additional clinical testing and development efforts. Words such as "look forward," "designed," "believe," "appears" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Sunesis' current expectations. Forward-looking statements involve risks and uncertainties. Sunesis' actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risk
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
2. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Transcept Pharmaceuticals, Inc. to Present at 2007 BIO Investor Forum
6. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
7. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
8. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
9. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
11. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... Africa (PRWEB) July 23, 2014 It all ... in an attempt to find common ground. Willem de Liefde ... the crossroads of their lives or careers. , Willem wrote ... deeper and look beyond the surface of things. It is ... future, driven by care and commitment. , This book represents ...
(Date:7/22/2014)... Los Angeles, CA (PRWEB) July 22, 2014 ... is expected to increase in size through 2022, according ... ways to improve their appearance can benefit from a ... eye serum review for women is now available at ... to access and includes instant links to many of ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Mona Khan ... certification on August 15th & 16th, 2014, at the ... only structured and nationally accredited Bollywood workout was launched ... by the globally appealing Bollywood culture, Bombay Jam® is ... easy to follow and designed with authentic Bollywood flavor. ...
(Date:7/22/2014)... Dr. Dental is excited to announce the redesign ... in mind, one of the main differences from the old ... navigation very easy. Dr. Dental is renowned for having exceptional ... dentist affordable, convenient and fun, and the new website mirrors ... appointment scheduling system right on the home page where a ...
(Date:7/22/2014)... Va. (PRWEB) July 22, 2014 ... 10, at the Ronald Reagan Building and International ... Forward: Warriors, Military Families and Civilian Communities,” will ... (registration opens at 7:30 a.m.) and cohosted by ... the National Defense Industrial Association (NDIA). USAA is ...
Breaking Medicine News(10 mins):Health News:Willem de Liefde, Author and Management Expert, Releases New Guide for Understanding Friends, Family, Co-Workers and Ourselves 2Health News:Eye Serum Review for Women: New Guide Published Online by Top Review Website 2Health News:Mona Khan Company Announces Bombay Jam® Instructor Certification in Los Angeles in August 2014 2Health News:Mona Khan Company Announces Bombay Jam® Instructor Certification in Los Angeles in August 2014 3Health News:Dr. Dental Reveals Exciting New Website 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 3
... Elbit Imaging Ltd.,(Nasdaq: EMITF ) ("EI" or ... of 2008., Loss for the first quarter of ... of which loss of NIS 27.3 million,(approximately US$ 7.7 ... while profit of NIS 23.8 million (approximately US$ 6.7,million) ...
... May 29 Subjects with type 1 or ... more frequently and,use the results to adjust treatment ... collection of state-of-the-art reports that,comprise a Special Supplement ... of Diabetes Technology & Therapeutics, a peer-reviewed journal ...
... New research from the Oregon Health & Science ... a wellspring of hope to many patients. , Researchers ... DNA abnormalities that can occur in a gene called ... kinds of acral and mucosal melanomas, which are less ...
... by Tel Aviv University researcher Prof. Illana Gozes may ... disease. This compound could also treat a number of ... schizophrenia and Parkinson,s, by limiting damage to the brain. ... found to protect American patients with mild cognitive damage ...
... bacteria break their metabolic processes into chunks. That may ... have now figured out the factors that tend to ... Santa Fe Institute and Stanford University, together with Anat ... University, constructed the metabolic networks of many species of ...
... used to prepare a powerful cancer-killing agent may be ... the natural product attacks, according to findings published in ... Chemistry. , Building on their earlier research into neocarzinostatin, ... University of Wisconsin, Madison discovered that one of the ...
Cached Medicine News:Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 2Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 3Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 4Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 5Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 6Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 7Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 8Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 9Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 10Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 11Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 12Health News:Elbit Imaging Ltd. Announces First Quarter Results for 2008 13Health News:Self-Monitoring of Blood Glucose Highly Effective in Diabetes Care, According to a Special Issue of Diabetes Technology and Therapeutics 2Health News:Self-Monitoring of Blood Glucose Highly Effective in Diabetes Care, According to a Special Issue of Diabetes Technology and Therapeutics 3Health News:OHSU Cancer Instutute researchers find abnormalities in gene for melanoma 2Health News:Appealing the death sentence for brain cells 2Health News:Enzyme may hold key to improved targeting of cancer-fighting drugs 2
(Date:7/22/2014)... July 22, 2014  Jazz Pharmaceuticals plc (Nasdaq: ... its 2014 second quarter financial results on Tuesday, August ... Company management will host a live audio webcast immediately ... to provide a business and financial update and discuss ... may access the live audio webcast via the Investors ...
(Date:7/22/2014)... , July 22, 2014 Research ... "Cell Culture Market by Equipment, by Reagent, by ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... organisms. Cell culture is one of the most important ... also the largest application segment of the cell culture ...
(Date:7/22/2014)... 22, 2014 Legislation backed by the ... Local Pharmacies Act of 2014") championing so-called "any ... undermine the availability of lower cost preferred pharmacy ... over the next 10 years, according to new ... Pharmaceutical Care Management Association (PCMA). The ...
Breaking Medicine Technology:Jazz Pharmaceuticals to Report 2014 Second Quarter Financial Results on August 5, 2014 2Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 2Global Cell Culture (Bioreactor, Incubator, Centrifuge) Market - Forecast to 2018 3New Study: H.R. 4577 to Cost $21 Billion over 10 Years 2New Study: H.R. 4577 to Cost $21 Billion over 10 Years 3
... 2011 West Pharmaceutical Services, Inc. (NYSE: WST ... investor conferences. Management will attend the 9th Annual ... NY.  Management will present an overview of West,s business and ... Management will also attend the UBS 2011 Global ...
... 2011 Prescription monitoring laboratory and clinical partner ... its Safe Use Treatment Monitoring Solution™. Consistent with ... compliant with the FDA,s Opioid Risk and Evaluation ... for controlled substances.  The program aims to support ...
Cached Medicine Technology:Dominion Diagnostics Leads Fight Against Prescription Drug Abuse with Safe Use Treatment Monitoring Solution 2
... Rail clamp with self-adjusting adaptability to ... permits complete versatility of angling at the ... The 3/D Swinger permits it to be ... With the Iron Intern®, a simple adjustment ...
Stainless steel construction to withstand sterilization modalities (EtO) Wide angle of view...
Inquire...
Inquire...
Medicine Products: